GlassScriptPhysician profile
Dmitri Y Belov
NPI 1952632390
$3,773.59
in general payments reported to CMS, 2019-2025
24 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $84.10 · 2021: $54.20 · 2022: $221 · 2023: $762 · 2024: $681 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207 · Travel and Lodging: $266 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.64 |
| Travel and Lodging | $266.27 |
| Education | $197.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.60 | 2019-2025 | Jardiance |
| Pfizer INC. | $456.65 | 2019-2025 | |
| Cvrx, INC. | $399.58 | 2024-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $324.05 | 2019-2025 | |
| Abbott Laboratories | $264.38 | 2019-2025 | Navitor, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Actelion Pharmaceuticals US, INC. | $240.06 | 2023 | Uptravi, Opsumit |
| Abiomed | $204.53 | 2019-2025 | Impella |
| Scpharmaceuticals INC. | $196.74 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $179.38 | 2019-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $158.45 | 2019-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $138.55 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $128.10 | 2022-2025 | |
| Boston Scientific Corporation | $100.00 | 2025 | General - Therapies |
| Merck Sharp & Dohme LLC | $98.28 | 2022-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.62 | 2019-2023 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $66.92 | 2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $47.54 | 2024 | |
| Esperion Therapeutics, INC. | $44.37 | 2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $42.23 | 2022-2025 | Wainua |
| Amgen INC. | $35.90 | 2019-2025 | Repatha |
| Bridgebio Pharma, INC. | $32.09 | 2025 | Attruby |
| Baxter Healthcare | $25.99 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $19.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitri Belov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.